Teow Sin-Yeang, Yap Hooi-Yeen, Peh Suat-Cheng
Sunway Institute for Healthcare Development (SIHD), Sunway University, Jalan Universiti, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia.
Anatomical Pathology Department, Sunway Medical Centre, Jalan Lagoon Selatan, Bandar Sunway, 47500 Subang Jaya, Selangor Darul Ehsan, Malaysia.
J Pathog. 2017;2017:7349268. doi: 10.1155/2017/7349268. Epub 2017 Dec 31.
Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets B-lymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as nasopharyngeal carcinoma (NPC), Burkitt's lymphoma (BL), and Hodgkin's lymphoma (HL). Recent findings have shown promise on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly on NPC. In-depth investigations are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV targets for NPC immunotherapy and therapeutic vaccine development as well as addressing the underlying challenges in the process of bringing the therapy and vaccination from the bench to bedside.
爱泼斯坦-巴尔病毒（EBV）是一种感染全球90%以上人口的病原体。EBV主要靶向B淋巴细胞和上皮细胞，同时其中一些会感染单核细胞/巨噬细胞、T淋巴细胞和树突状细胞（DC）。EBV感染本身不会导致死亡，但这种感染一直与某些类型的癌症相关，如鼻咽癌（NPC）、伯基特淋巴瘤（BL）和霍奇金淋巴瘤（HL）。最近的研究结果显示了通过免疫治疗方法靶向EBV蛋白进行癌症治疗的前景。一些研究还表明，采用基于EBV的治疗性疫苗预防EBV相关癌症，特别是对鼻咽癌，取得了成功。目前正在进行深入研究，以完善当前的治疗和疫苗接种策略。在本综述中，我们讨论了鼻咽癌免疫治疗和治疗性疫苗开发中极具潜力的EBV靶点，以及在将治疗和疫苗接种从实验室应用到临床过程中面临的潜在挑战。
